42 Chapter 2 69. Fernandez A, Restrepo R, Villa P, Garcés J, Montero G. Angioplasty with stent vs. coronary artery bypass grafting in multivessel disease (ACIRE). Colomb J Cardiol. 2009;16(2). 70. Fernandez A, Aboodi MS, Milewski K, Delgado JA, Rodríguez A, Granada JF. Comparison of Adverse Cardiovascular Events and Bleeding Complications of Loading Dose of Clopidogrel 300 mg Versus 600 mg in Stable Patients Undergoing Elective Percutaneous Intervention ( from the CADICE Study ). AJC. 2011;107(1):6–9. 71. Rueda-Clausen CF, Lahera V, Calderón J, Bolivar IC, Castillo VR, Gutiérrez M, et al. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol. 2010;139(1):32–41. 72. Vesga BE, Echeverri D. Resistencia al ácido acetil salicílico en pacientes con enfermedad coronaria. Rev Colomb Cardiol. 2006;13(1):13–22. 73. Gambogi RA, Baldizzoni M, Albornoz H, Ketzoian C, Cabrera M, Saona G, et al. Prevención secundaria en pacientes revascularizados coronarios en Uruguay : descripción de un programa , evaluación del control de los factores de riesgo y efecto en la mortalidad. Clin Invest Ateriosc. 2010;22(2):59–69. 74. Dayan V, Perez D, Silva E, Soca G, Estigarribia J. CABG and preoperative use of beta-blockers in patients with stable angina are associated with better cardiovascular survival. Brazilian J Cardiovasc Surg. 2018;33(1):47–53. 75. Vazquez H, Burdiat G, Alonso P, Sandoya E, Tejada J. Control del riesgo cardiovascular postinternación en pacientes coronarios. Rev Urug Cardiol. 2011;26:108–14. 76. de Souza Groia Veloso RC, Cruzeiro M, Menezes Dias B, Moreira Reis AM. Profile of use and access to statins in patients with coronary arterial disease in an outpatient clinic of a teaching hospital. Curr Med Res Opin. 2020;36(9):1427–31. 77. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE ( WHO-PREMISE ). Bull World Health Organ. 2005;83(11):820–31. 78. Castro LT De, Santos IDS, Goulart AC, Pereira C, Staniak HL, Bittencourt MS, et al. Elevated High-Sensitivity Troponin I in the Stabilized Phase after an Acute Coronary Syndrome Predicts All-Cause and Cardiovascular Mortality in a Highly Admixed Population : A 7-Year Cohort. Arq Bras Cardiol. 2019;112(3):230–7. 79. Henrique L, Gowdak W, Arantes RL, Paula FJ De, Krieger EM, Jayme J, et al. Underuse of American College of Cardiology / American Heart Association Guidelines in Hemodialysis Patients Underuse of American College of Cardiology / American Heart Association Guidelines in Hemodialysis Patients. Ren Fail. 2009;29:559–65. 80. Ogawa Indio do Brasil C, Avezum Á, Uint L, Del MI, Barros VM De, Youssef S, et al. Cardiovascular prevention in coronary heart disease patients : guidelines implementation in clinical practice. 2013;238–47. 81. Vianna CA, Gonzalez DA, Matijasevich A. Utilização de ácido acetilsalicílico ( AAS ) na prevenção de doenças cardiovasculares : um estudo de base populacional Aspirin use in cardiovascular disease prevention : a populationbased study. Cad Saúde Pública. 2012;28(6):1122–32. 82. Smedt D De, Backer T De, Petrovic M, Backer G De, Wood D, Kotseva K, et al. Chronic medication intake in patients with stable coronary heart disease across Europe : Evidence from the daily clinical practice . Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes ( EUROASPIRE IV ) Registry. Int J Cardiol. 2020;300:7–13. 83. Barth JH, Misra S, Aakre KM, Langlois MR, Watine J, Twomey PJ, et al. Why are clinical practice guidelines not followed?: The European Federation of Clinical Chemistry and Laboratory Medicine and European Union of Medical Specialists joint working group on Guidelines. Clin Chem Lab Med. 2016;54(7):1133–9. 84. Kotseva K, De Bacquer D, Jennings C, Gyberg V, De Backer G, Rydén L, et al. Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999–2013. Glob Heart. 2017;12(4):315-322.e3. 85. Achelrod D, Gray A, Preiss D, Mihaylova B. Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe. Eur J Prev Cardiol. 2017;24(4):426–36. 86. Oliveri R. Consenso SAC 2001. 1981;7–8. 87. Andrade MD. Diretrizes SBC 2004-2008. 88. Diretrizes SBC 2005- 2009. Arquivos Brasileiros de Cardiologia. 89. Cardiologia B De. Diretrizes SBC 2007- 2011. 2011. 90. Sociedade Brasileira de Cardiologia. Diretrizes da SBC 2009-2014. Soc Bras Cardiol. 2014;728. 91. Marianna Deway Andrade, Ariane Vieira Scarlatelli Macedo, Ana Luiza Russo Piuzana et al. Diretrizes da Sociedade Brasileira de Cardiologia: Pocket Book 2013-2015. Soc Bras Cardiol. 2015;7:1–599. 92. Kreutzer G, Directiva C, El H, Inst C, Fleming A, Uu CEE, et al. Consenso Prevención Cardiovascular. Rev Argent Cardiol. 2012;80(2). 93. Taddei C, Zhou B, Bixby H, Carrillo-Larco RM, Danaei G, Jackson RT, et al. Repositioning of the global epicentre of nonoptimal cholesterol. Nature. 2020;582(7810):73–7.
RkJQdWJsaXNoZXIy MTk4NDMw